Please provide your email address to receive an email when new articles are posted on . A novel SK ion channel inhibitor more often converted atrial fibrillation to sinus rhythm compared with placebo.
Acesion Pharma ApS has announced promising data from preclinical studies with AP-31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback